Effect of Administration of 3rd Generation Cephalosporin on the Digestive Carrying of 3rd Generation Cephalosporin-resistant Enterobacteriaceae (CEF-IMPACT)

• Status: Unknown status
• Trial end date: 2020-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study was to compare the frequency of occurrence of digestive carrying of 3rd generation cephalosporin-resistant enterobacteriaceae (EB C3G-R), acquired during hospitalization in one of the participating departments, between patients treated with ceftriaxone and patients treated with cefotaxime

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Centre Hospitalier Universitaire de Besancon
• Treatments: Cefotaxime; Cefoxitin; Ceftriaxone; Cephalosporins

Criteria

Inclusion Criteria:

• Age ≥ 18 years old

• Indication for antibiotic treatment with a 3rd generation injectable cephalosporin (cefotaxime or ceftriaxone)

• Signed Informed Consent

Exclusion Criteria:

• Hypersensitivity to ceftriaxone or cefotaxime, to another cephalosporin or to any of the excipients of the specialities concerned.

• History of severe hypersensitivity (e.g., anaphylactic reaction) to another class of antibacterial agent of the beta-lactam family (penicillins, monobactams and carbapenes)

• Subcutaneous administration of ceftriaxone

• Pregnant and breastfeeding woman

• Suspicion of Pseudomonas infection or documented Pseudomonas infection requiring ceftazidime treatment

• Suspicion of group III enterobacteriaceae infection or group III enterobacteriaceae infection requiring cefepime treatment